Geoffrey Beran Rose - Mar 1, 2024 Form 4/A Insider Report for Pulmonx Corp (LUNG)

Role
CHIEF COMMERCIAL OFFICER
Signature
/s/ Lauren Cristina, Attorney-in-Fact
Stock symbol
LUNG
Transactions as of
Mar 1, 2024
Transactions value $
$0
Form type
4/A
Date filed
3/7/2024, 08:02 PM
Date Of Original Report
Mar 5, 2024
Previous filing
Feb 26, 2024
Next filing
Mar 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LUNG Common Stock Award $0 +69.1K +28.8% $0.00 309K Mar 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LUNG Employee Stock Option (right to buy) Award $0 +34.5K $0.00 34.5K Mar 1, 2024 Common Stock 34.5K $9.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents grant of RSUs payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on March 1, 2024.
F2 The shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2024.

Remarks:

This amendment is being filed solely to correct the inadvertent typographical errors in the number of shares underlying the Employee Stock Option and Restricted Stock Units and the total securities owned after such transactions as reported in the original Form 4 filed with the SEC on March 5, 2024.